Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

Clinical trial NCT06670222 · RECRUITING

Trial details

NCT number: NCT06670222
Sponsor: Groupe Francophone des Myelodysplasies
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Low-risk Myelodysplastic Syndromes

Start date: 2025-07-22
Primary completion: 2026-08-24
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.